Fny Investment Advisers, LLC Genmab A/S Transaction History

Fny Investment Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 12, 2023	BUY	$34.88 - $43.22 $139,520 - $172,880	4,000 New	4,000 $151,000
Q1 2022 Apr 25, 2022	SELL	$30.95 - $39.68 $193,685 - $248,317	-6,258 Closed	0 $0
Q4 2021 Jan 10, 2022	BUY	$35.87 - $47.12 $224,474 - $294,876	6,258 New	6,258 $247,000
Q2 2021 Jul 14, 2021	SELL	$32.88 - $44.57 $493,200 - $668,550	-15,000 Closed	0 $0
Q1 2021 Apr 12, 2021	BUY	$30.92 - $44.4 $463,800 - $666,000	15,000 New	15,000 $492,000
Q4 2020 Jan 19, 2021	SELL	$33.66 - $40.76 $238,615 - $288,947	-7,089 Closed	0 $0
Q3 2020 Oct 09, 2020	BUY	$33.07 - $38.68 $234,433 - $274,202	7,089 New	7,089 $259,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Fny Investment Advisers, LLC with notifications on news.